POLIVY+BR is a fixed course of treatment administered every 21 days for 6 cycles

Recommended dosing schedule for POLIVY (polatuzumab vedotin) 1

POLIVY is typically administered in an outpatient setting, such as an infusion center

  • POLIVY, bendamustine, and rituximab can be administered in any order on Day 1 of each cycle
  • If the patient is not already premedicated, administer premedication with an antihistamine and antipyretic at least 30 minutes prior to POLIVY
  • Do not mix POLIVY with or administer through the same infusion line as other medicinal products
  • Consider prophylactic G-CSF administration for potential neutropenia
  • If a planned dose of POLIVY is missed, administer as soon as possible. Adjust schedule of administration to maintain a 21-day interval between doses
  • See the full Prescribing Information for bendamustine and rituximab product prior to initiation

G-CSF=granulocyte colony-stimulating factor.

POLIVY is available to order from authorized distributors

Dose modifications for POLIVY (polatuzumab vedotin)

POLIVY dose modifications for peripheral neuropathy1

Severity Dose Modification
Grade 2-3 Hold POLIVY dosing until improvement to Grade 1 or lower.
If recovered to Grade 1 or lower on or before Day 14, restart POLIVY with the next cycle at a permanently reduced dose of 1.4 mg/kg.
If a prior dose reduction to 1.4 mg/kg has occurred, discontinue POLIVY.
If not recovered to Grade 1 or lower on or before Day 14, discontinue POLIVY.
Grade 4 Discontinue POLIVY.

POLIVY dose modifications for infusion-related reactions 1

Severity Dose Modification
Grade 1-3 Interrupt POLIVY infusion and give supportive treatment.
For the first instance of Grade 3 wheezing, bronchospasm, or generalized urticaria, permanently discontinue POLIVY.
For recurrent Grade 2 wheezing or urticaria, or for recurrence of any Grade 3 symptoms, permanently discontinue POLIVY.
Otherwise, upon complete resolution of symptoms, infusion may be resumed at 50% of the rate achieved prior to interruption. In the absence of infusion-related symptoms, the rate of infusion may be escalated in increments of 50 mg/hour every 30 minutes.
For the next cycle, infuse POLIVY over 90 minutes. If no infusion-related reaction occurs, subsequent infusions may be administered over 30 minutes. Administer premedication for all cycles.
Grade 4 Stop POLIVY infusion immediately.
Give supportive treatment.
Permanently discontinue POLIVY.

POLIVY+BR dose modifications for myelosuppression1

Severity* Dose Modification
Grade 3-4
neutropenia

Hold all treatment until ANC recovers to >1000/μL.
If ANC recovers to >1000/μL on or before Day 7, resume all treatment without any additional dose reductions. Consider G-CSF prophylaxis for subsequent cycles, if not previously given. 
If ANC recovers to >1000/μL after Day 7:

  • Restart all treatment. Consider G-CSF prophylaxis for subsequent cycles, if not previously given. If prophylaxis was given, consider dose reduction of bendamustine
  • If dose reduction of bendamustine has already occurred, consider dose reduction of POLIVY to 1.4 mg/kg
Grade 3-4
thrombocytopenia

Hold all treatment until platelets recover to >75,000/μL.
If platelets recover to >75,000/μL on or before Day 7, resume all treatment without any additional dose reductions.
If platelets recover to >75,000/μL after Day 7:

  • Restart all treatment, with a dose reduction of bendamustine
  • If a dose reduction of bendamustine has already occurred, consider dose reduction of POLIVY to 1.4 mg/kg 

*Severity on Day 1 of any cycle.
If primary cause is due to lymphoma, the dose of bendamustine may not need to be reduced.
ANC=absolute neutrophil count.